Drug intelligence / Profile preview

177Lu-DTPA-SC16.56

Development stage: Phase 1
Lead developer: Memorial Sloan Kettering Cancer Center
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**177Lu-DTPA-SC16.56** is a targeted radiopharmaceutical designed for the treatment of cancers that overexpress delta-like ligand 3 (DLL3), particularly **small-cell lung cancer** and **neuroendocrine prostate cancer**. The drug is a radioimmunoconjugate composed of a humanized monoclonal antibody (SC16.56) that specifically binds DLL3, conjugated with DTPA as a chelator holding the radionuclide **lutetium-177 (177Lu)**. When administered, the antibody binds to DLL3 on the surface of cancer cells, delivering cytotoxic beta-emitting radiation specifically to DLL3-expressing tumor cells, thus limiting off-target toxicity. This makes 177Lu-DTPA-SC16.56 a form of targeted radioimmunotherapy, aiming to improve efficacy and reduce systemic side effects compared to conventional radiotherapy[1][2][7][9]. The drug is currently under investigation primarily for safety and initial efficacy in a Phase 1 clinical trial for neuroendocrine carcinomas of the lung and prostate.

Other names: [177Lu]Lu-DTPA-SC16.56

Targets

DLL3 (Delta-like ligand 3)

Beyond the preview

Go deeper on 177Lu-DTPA-SC16.56.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 177Lu-DTPA-SC16.56.

Explore the full profile